世界の軽度認知障害治療市場規模・現状・予測2021-2027

【英語タイトル】Global Mild Cognitive Impairment Therapeutic Market Size, Status and Forecast 2021-2027

QYResearchが出版した調査資料(QY21APR3790)・商品コード:QY21APR3790
・発行会社(調査会社):QYResearch
・発行日:2021年4月(※2024年版があります。お問い合わせください)
・ページ数:131
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査資料では、軽度認知障害治療の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(BAN-2401、ボスチニブ、ブレキサノロン、CSP-1103、その他)、用途別市場規模(病院、クリニック、その他)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・軽度認知障害治療の市場動向
・企業の競争状況、市場シェア
・軽度認知障害治療の種類別市場規模(BAN-2401、ボスチニブ、ブレキサノロン、CSP-1103、その他)
・軽度認知障害治療の用途別市場規模(病院、クリニック、その他)
・軽度認知障害治療の北米市場規模2016-2027(アメリカ、カナダ)
・軽度認知障害治療の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・軽度認知障害治療のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・軽度認知障害治療の中南米市場規模2016-2027(メキシコ、ブラジル)
・軽度認知障害治療の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(AgeneBio Inc、Avraham Pharmaceuticals Ltd、CereSpir Inc、ConSynance Therapeutics Inc、Eisai Co Ltd、Eli Lilly and Company、Ensol Biosciences Inc、Genzyme Corp、IntelGenx Corp、Krenitsky Pharmaceuticals Inc、Merck & Co Inc、Nanotherapeutics Inc、Neuron Biopharma SA、Pfizer Inc、Sage Therapeutics Inc、SBI Pharmaceuticals Co Ltd、Suven Life Sciences Ltd、Takeda Pharmaceutical Company Ltd、Therapix Biosciences Ltd)
・結論
【レポートの概要】

Market Analysis and Insights: Global Mild Cognitive Impairment Therapeutic Market
The global Mild Cognitive Impairment Therapeutic market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Mild Cognitive Impairment Therapeutic market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Mild Cognitive Impairment Therapeutic market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Mild Cognitive Impairment Therapeutic market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Mild Cognitive Impairment Therapeutic market.

Global Mild Cognitive Impairment Therapeutic Scope and Market Size
Mild Cognitive Impairment Therapeutic market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Mild Cognitive Impairment Therapeutic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
BAN-2401
Bosutinib
Brexanolone
CSP-1103
Others

Segment by Application
Hospital
Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AgeneBio Inc
Avraham Pharmaceuticals Ltd
CereSpir Inc
ConSynance Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Company
Ensol Biosciences Inc
Genzyme Corp
IntelGenx Corp
ConSynance Therapeutics Inc
Eisai Co Ltd
Nanotherapeutics Inc
Neuron Biopharma SA
Pfizer Inc
Sage Therapeutics Inc
SBI Pharmaceuticals Co Ltd
Suven Life Sciences Ltd

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Mild Cognitive Impairment Therapeutic Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 BAN-2401
1.2.3 Bosutinib
1.2.4 Brexanolone
1.2.5 CSP-1103
1.2.6 Others
1.3 Market by Application
1.3.1 Global Mild Cognitive Impairment Therapeutic Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Mild Cognitive Impairment Therapeutic Market Perspective (2016-2027)
2.2 Mild Cognitive Impairment Therapeutic Growth Trends by Regions
2.2.1 Mild Cognitive Impairment Therapeutic Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Mild Cognitive Impairment Therapeutic Historic Market Share by Regions (2016-2021)
2.2.3 Mild Cognitive Impairment Therapeutic Forecasted Market Size by Regions (2022-2027)
2.3 Mild Cognitive Impairment Therapeutic Industry Dynamic
2.3.1 Mild Cognitive Impairment Therapeutic Market Trends
2.3.2 Mild Cognitive Impairment Therapeutic Market Drivers
2.3.3 Mild Cognitive Impairment Therapeutic Market Challenges
2.3.4 Mild Cognitive Impairment Therapeutic Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Mild Cognitive Impairment Therapeutic Players by Revenue
3.1.1 Global Top Mild Cognitive Impairment Therapeutic Players by Revenue (2016-2021)
3.1.2 Global Mild Cognitive Impairment Therapeutic Revenue Market Share by Players (2016-2021)
3.2 Global Mild Cognitive Impairment Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Mild Cognitive Impairment Therapeutic Revenue
3.4 Global Mild Cognitive Impairment Therapeutic Market Concentration Ratio
3.4.1 Global Mild Cognitive Impairment Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Mild Cognitive Impairment Therapeutic Revenue in 2020
3.5 Mild Cognitive Impairment Therapeutic Key Players Head office and Area Served
3.6 Key Players Mild Cognitive Impairment Therapeutic Product Solution and Service
3.7 Date of Enter into Mild Cognitive Impairment Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Mild Cognitive Impairment Therapeutic Breakdown Data by Type
4.1 Global Mild Cognitive Impairment Therapeutic Historic Market Size by Type (2016-2021)
4.2 Global Mild Cognitive Impairment Therapeutic Forecasted Market Size by Type (2022-2027)

5 Mild Cognitive Impairment Therapeutic Breakdown Data by Application
5.1 Global Mild Cognitive Impairment Therapeutic Historic Market Size by Application (2016-2021)
5.2 Global Mild Cognitive Impairment Therapeutic Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Mild Cognitive Impairment Therapeutic Market Size (2016-2027)
6.2 North America Mild Cognitive Impairment Therapeutic Market Size by Type
6.2.1 North America Mild Cognitive Impairment Therapeutic Market Size by Type (2016-2021)
6.2.2 North America Mild Cognitive Impairment Therapeutic Market Size by Type (2022-2027)
6.2.3 North America Mild Cognitive Impairment Therapeutic Market Size by Type (2016-2027)
6.3 North America Mild Cognitive Impairment Therapeutic Market Size by Application
6.3.1 North America Mild Cognitive Impairment Therapeutic Market Size by Application (2016-2021)
6.3.2 North America Mild Cognitive Impairment Therapeutic Market Size by Application (2022-2027)
6.3.3 North America Mild Cognitive Impairment Therapeutic Market Size by Application (2016-2027)
6.4 North America Mild Cognitive Impairment Therapeutic Market Size by Country
6.4.1 North America Mild Cognitive Impairment Therapeutic Market Size by Country (2016-2021)
6.4.2 North America Mild Cognitive Impairment Therapeutic Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Mild Cognitive Impairment Therapeutic Market Size (2016-2027)
7.2 Europe Mild Cognitive Impairment Therapeutic Market Size by Type
7.2.1 Europe Mild Cognitive Impairment Therapeutic Market Size by Type (2016-2021)
7.2.2 Europe Mild Cognitive Impairment Therapeutic Market Size by Type (2022-2027)
7.2.3 Europe Mild Cognitive Impairment Therapeutic Market Size by Type (2016-2027)
7.3 Europe Mild Cognitive Impairment Therapeutic Market Size by Application
7.3.1 Europe Mild Cognitive Impairment Therapeutic Market Size by Application (2016-2021)
7.3.2 Europe Mild Cognitive Impairment Therapeutic Market Size by Application (2022-2027)
7.3.3 Europe Mild Cognitive Impairment Therapeutic Market Size by Application (2016-2027)
7.4 Europe Mild Cognitive Impairment Therapeutic Market Size by Country
7.4.1 Europe Mild Cognitive Impairment Therapeutic Market Size by Country (2016-2021)
7.4.2 Europe Mild Cognitive Impairment Therapeutic Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size (2016-2027)
8.2 Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Type
8.2.1 Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Type (2016-2027)
8.3 Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Application
8.3.1 Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Application (2016-2027)
8.4 Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Region
8.4.1 Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Mild Cognitive Impairment Therapeutic Market Size (2016-2027)
9.2 Latin America Mild Cognitive Impairment Therapeutic Market Size by Type
9.2.1 Latin America Mild Cognitive Impairment Therapeutic Market Size by Type (2016-2021)
9.2.2 Latin America Mild Cognitive Impairment Therapeutic Market Size by Type (2022-2027)
9.2.3 Latin America Mild Cognitive Impairment Therapeutic Market Size by Type (2016-2027)
9.3 Latin America Mild Cognitive Impairment Therapeutic Market Size by Application
9.3.1 Latin America Mild Cognitive Impairment Therapeutic Market Size by Application (2016-2021)
9.3.2 Latin America Mild Cognitive Impairment Therapeutic Market Size by Application (2022-2027)
9.3.3 Latin America Mild Cognitive Impairment Therapeutic Market Size by Application (2016-2027)
9.4 Latin America Mild Cognitive Impairment Therapeutic Market Size by Country
9.4.1 Latin America Mild Cognitive Impairment Therapeutic Market Size by Country (2016-2021)
9.4.2 Latin America Mild Cognitive Impairment Therapeutic Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size (2016-2027)
10.2 Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Type
10.2.1 Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Type (2016-2027)
10.3 Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Application
10.3.1 Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Application (2016-2027)
10.4 Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Country
10.4.1 Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AgeneBio Inc
11.1.1 AgeneBio Inc Company Details
11.1.2 AgeneBio Inc Business Overview
11.1.3 AgeneBio Inc Mild Cognitive Impairment Therapeutic Introduction
11.1.4 AgeneBio Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.1.5 AgeneBio Inc Recent Development
11.2 Avraham Pharmaceuticals Ltd
11.2.1 Avraham Pharmaceuticals Ltd Company Details
11.2.2 Avraham Pharmaceuticals Ltd Business Overview
11.2.3 Avraham Pharmaceuticals Ltd Mild Cognitive Impairment Therapeutic Introduction
11.2.4 Avraham Pharmaceuticals Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.2.5 Avraham Pharmaceuticals Ltd Recent Development
11.3 CereSpir Inc
11.3.1 CereSpir Inc Company Details
11.3.2 CereSpir Inc Business Overview
11.3.3 CereSpir Inc Mild Cognitive Impairment Therapeutic Introduction
11.3.4 CereSpir Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.3.5 CereSpir Inc Recent Development
11.4 ConSynance Therapeutics Inc
11.4.1 ConSynance Therapeutics Inc Company Details
11.4.2 ConSynance Therapeutics Inc Business Overview
11.4.3 ConSynance Therapeutics Inc Mild Cognitive Impairment Therapeutic Introduction
11.4.4 ConSynance Therapeutics Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.4.5 ConSynance Therapeutics Inc Recent Development
11.5 Eisai Co Ltd
11.5.1 Eisai Co Ltd Company Details
11.5.2 Eisai Co Ltd Business Overview
11.5.3 Eisai Co Ltd Mild Cognitive Impairment Therapeutic Introduction
11.5.4 Eisai Co Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.5.5 Eisai Co Ltd Recent Development
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Details
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Mild Cognitive Impairment Therapeutic Introduction
11.6.4 Eli Lilly and Company Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.6.5 Eli Lilly and Company Recent Development
11.7 Ensol Biosciences Inc
11.7.1 Ensol Biosciences Inc Company Details
11.7.2 Ensol Biosciences Inc Business Overview
11.7.3 Ensol Biosciences Inc Mild Cognitive Impairment Therapeutic Introduction
11.7.4 Ensol Biosciences Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.7.5 Ensol Biosciences Inc Recent Development
11.8 Genzyme Corp
11.8.1 Genzyme Corp Company Details
11.8.2 Genzyme Corp Business Overview
11.8.3 Genzyme Corp Mild Cognitive Impairment Therapeutic Introduction
11.8.4 Genzyme Corp Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.8.5 Genzyme Corp Recent Development
11.9 IntelGenx Corp
11.9.1 IntelGenx Corp Company Details
11.9.2 IntelGenx Corp Business Overview
11.9.3 IntelGenx Corp Mild Cognitive Impairment Therapeutic Introduction
11.9.4 IntelGenx Corp Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.9.5 IntelGenx Corp Recent Development
11.10 Krenitsky Pharmaceuticals Inc
11.10.1 Krenitsky Pharmaceuticals Inc Company Details
11.10.2 Krenitsky Pharmaceuticals Inc Business Overview
11.10.3 Krenitsky Pharmaceuticals Inc Mild Cognitive Impairment Therapeutic Introduction
11.10.4 Krenitsky Pharmaceuticals Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.10.5 Krenitsky Pharmaceuticals Inc Recent Development
11.11 Merck & Co Inc
11.11.1 Merck & Co Inc Company Details
11.11.2 Merck & Co Inc Business Overview
11.11.3 Merck & Co Inc Mild Cognitive Impairment Therapeutic Introduction
11.11.4 Merck & Co Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.11.5 Merck & Co Inc Recent Development
11.12 Nanotherapeutics Inc
11.12.1 Nanotherapeutics Inc Company Details
11.12.2 Nanotherapeutics Inc Business Overview
11.12.3 Nanotherapeutics Inc Mild Cognitive Impairment Therapeutic Introduction
11.12.4 Nanotherapeutics Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.12.5 Nanotherapeutics Inc Recent Development
11.13 Neuron Biopharma SA
11.13.1 Neuron Biopharma SA Company Details
11.13.2 Neuron Biopharma SA Business Overview
11.13.3 Neuron Biopharma SA Mild Cognitive Impairment Therapeutic Introduction
11.13.4 Neuron Biopharma SA Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.13.5 Neuron Biopharma SA Recent Development
11.14 Pfizer Inc
11.14.1 Pfizer Inc Company Details
11.14.2 Pfizer Inc Business Overview
11.14.3 Pfizer Inc Mild Cognitive Impairment Therapeutic Introduction
11.14.4 Pfizer Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.14.5 Pfizer Inc Recent Development
11.15 Sage Therapeutics Inc
11.15.1 Sage Therapeutics Inc Company Details
11.15.2 Sage Therapeutics Inc Business Overview
11.15.3 Sage Therapeutics Inc Mild Cognitive Impairment Therapeutic Introduction
11.15.4 Sage Therapeutics Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.15.5 Sage Therapeutics Inc Recent Development
11.16 SBI Pharmaceuticals Co Ltd
11.16.1 SBI Pharmaceuticals Co Ltd Company Details
11.16.2 SBI Pharmaceuticals Co Ltd Business Overview
11.16.3 SBI Pharmaceuticals Co Ltd Mild Cognitive Impairment Therapeutic Introduction
11.16.4 SBI Pharmaceuticals Co Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.16.5 SBI Pharmaceuticals Co Ltd Recent Development
11.17 Suven Life Sciences Ltd
11.17.1 Suven Life Sciences Ltd Company Details
11.17.2 Suven Life Sciences Ltd Business Overview
11.17.3 Suven Life Sciences Ltd Mild Cognitive Impairment Therapeutic Introduction
11.17.4 Suven Life Sciences Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.17.5 Suven Life Sciences Ltd Recent Development
11.18 Takeda Pharmaceutical Company Ltd
11.18.1 Takeda Pharmaceutical Company Ltd Company Details
11.18.2 Takeda Pharmaceutical Company Ltd Business Overview
11.18.3 Takeda Pharmaceutical Company Ltd Mild Cognitive Impairment Therapeutic Introduction
11.18.4 Takeda Pharmaceutical Company Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
11.18.5 Takeda Pharmaceutical Company Ltd Recent Development
11.18 Therapix Biosciences Ltd
.1 Therapix Biosciences Ltd Company Details
.2 Therapix Biosciences Ltd Business Overview
.3 Therapix Biosciences Ltd Mild Cognitive Impairment Therapeutic Introduction
.4 Therapix Biosciences Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021)
.5 Therapix Biosciences Ltd Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Mild Cognitive Impairment Therapeutic Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of BAN-2401
Table 3. Key Players of Bosutinib
Table 4. Key Players of Brexanolone
Table 5. Key Players of CSP-1103
Table 6. Key Players of Others
Table 7. Global Mild Cognitive Impairment Therapeutic Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Mild Cognitive Impairment Therapeutic Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Mild Cognitive Impairment Therapeutic Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Mild Cognitive Impairment Therapeutic Market Share by Regions (2016-2021)
Table 11. Global Mild Cognitive Impairment Therapeutic Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Mild Cognitive Impairment Therapeutic Market Share by Regions (2022-2027)
Table 13. Mild Cognitive Impairment Therapeutic Market Trends
Table 14. Mild Cognitive Impairment Therapeutic Market Drivers
Table 15. Mild Cognitive Impairment Therapeutic Market Challenges
Table 16. Mild Cognitive Impairment Therapeutic Market Restraints
Table 17. Global Mild Cognitive Impairment Therapeutic Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Mild Cognitive Impairment Therapeutic Market Share by Players (2016-2021)
Table 19. Global Top Mild Cognitive Impairment Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Mild Cognitive Impairment Therapeutic as of 2020)
Table 20. Ranking of Global Top Mild Cognitive Impairment Therapeutic Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Mild Cognitive Impairment Therapeutic Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Mild Cognitive Impairment Therapeutic Product Solution and Service
Table 24. Date of Enter into Mild Cognitive Impairment Therapeutic Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Mild Cognitive Impairment Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Mild Cognitive Impairment Therapeutic Revenue Market Share by Type (2016-2021)
Table 28. Global Mild Cognitive Impairment Therapeutic Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Mild Cognitive Impairment Therapeutic Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Mild Cognitive Impairment Therapeutic Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Mild Cognitive Impairment Therapeutic Revenue Market Share by Application (2016-2021)
Table 32. Global Mild Cognitive Impairment Therapeutic Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Mild Cognitive Impairment Therapeutic Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Mild Cognitive Impairment Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Mild Cognitive Impairment Therapeutic Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Mild Cognitive Impairment Therapeutic Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Mild Cognitive Impairment Therapeutic Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Mild Cognitive Impairment Therapeutic Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Mild Cognitive Impairment Therapeutic Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Mild Cognitive Impairment Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Mild Cognitive Impairment Therapeutic Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Mild Cognitive Impairment Therapeutic Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Mild Cognitive Impairment Therapeutic Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Mild Cognitive Impairment Therapeutic Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Mild Cognitive Impairment Therapeutic Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Mild Cognitive Impairment Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Mild Cognitive Impairment Therapeutic Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Mild Cognitive Impairment Therapeutic Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Mild Cognitive Impairment Therapeutic Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Mild Cognitive Impairment Therapeutic Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Mild Cognitive Impairment Therapeutic Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size by Country (2022-2027) & (US$ Million)
Table 64. AgeneBio Inc Company Details
Table 65. AgeneBio Inc Business Overview
Table 66. AgeneBio Inc Mild Cognitive Impairment Therapeutic Product
Table 67. AgeneBio Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 68. AgeneBio Inc Recent Development
Table 69. Avraham Pharmaceuticals Ltd Company Details
Table 70. Avraham Pharmaceuticals Ltd Business Overview
Table 71. Avraham Pharmaceuticals Ltd Mild Cognitive Impairment Therapeutic Product
Table 72. Avraham Pharmaceuticals Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 73. Avraham Pharmaceuticals Ltd Recent Development
Table 74. CereSpir Inc Company Details
Table 75. CereSpir Inc Business Overview
Table 76. CereSpir Inc Mild Cognitive Impairment Therapeutic Product
Table 77. CereSpir Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 78. CereSpir Inc Recent Development
Table 79. ConSynance Therapeutics Inc Company Details
Table 80. ConSynance Therapeutics Inc Business Overview
Table 81. ConSynance Therapeutics Inc Mild Cognitive Impairment Therapeutic Product
Table 82. ConSynance Therapeutics Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 83. ConSynance Therapeutics Inc Recent Development
Table 84. Eisai Co Ltd Company Details
Table 85. Eisai Co Ltd Business Overview
Table 86. Eisai Co Ltd Mild Cognitive Impairment Therapeutic Product
Table 87. Eisai Co Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 88. Eisai Co Ltd Recent Development
Table 89. Eli Lilly and Company Company Details
Table 90. Eli Lilly and Company Business Overview
Table 91. Eli Lilly and Company Mild Cognitive Impairment Therapeutic Product
Table 92. Eli Lilly and Company Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 93. Eli Lilly and Company Recent Development
Table 94. Ensol Biosciences Inc Company Details
Table 95. Ensol Biosciences Inc Business Overview
Table 96. Ensol Biosciences Inc Mild Cognitive Impairment Therapeutic Product
Table 97. Ensol Biosciences Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 98. Ensol Biosciences Inc Recent Development
Table 99. Genzyme Corp Company Details
Table 100. Genzyme Corp Business Overview
Table 101. Genzyme Corp Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 102. Genzyme Corp Recent Development
Table 103. IntelGenx Corp Company Details
Table 104. IntelGenx Corp Business Overview
Table 105. IntelGenx Corp Mild Cognitive Impairment Therapeutic Product
Table 106. IntelGenx Corp Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 107. IntelGenx Corp Recent Development
Table 108. Krenitsky Pharmaceuticals Inc Company Details
Table 109. Krenitsky Pharmaceuticals Inc Business Overview
Table 110. Krenitsky Pharmaceuticals Inc Mild Cognitive Impairment Therapeutic Product
Table 111. Krenitsky Pharmaceuticals Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 112. Krenitsky Pharmaceuticals Inc Recent Development
Table 113. Merck & Co Inc Company Details
Table 114. Merck & Co Inc Business Overview
Table 115. Merck & Co Inc Mild Cognitive Impairment Therapeutic Product
Table 116. Merck & Co Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 117. Merck & Co Inc Recent Development
Table 118. Nanotherapeutics Inc Company Details
Table 119. Nanotherapeutics Inc Business Overview
Table 120. Nanotherapeutics Inc Mild Cognitive Impairment Therapeutic Product
Table 121. Nanotherapeutics Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 122. Nanotherapeutics Inc Recent Development
Table 123. Neuron Biopharma SA Company Details
Table 124. Neuron Biopharma SA Business Overview
Table 125. Neuron Biopharma SA Mild Cognitive Impairment Therapeutic Product
Table 126. Neuron Biopharma SA Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 127. Neuron Biopharma SA Recent Development
Table 128. Pfizer Inc Company Details
Table 129. Pfizer Inc Business Overview
Table 130. Pfizer Inc Mild Cognitive Impairment Therapeutic Product
Table 131. Pfizer Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 132. Pfizer Inc Recent Development
Table 133. Sage Therapeutics Inc Company Details
Table 134. Sage Therapeutics Inc Business Overview
Table 135. Sage Therapeutics Inc Mild Cognitive Impairment Therapeutic Product
Table 136. Sage Therapeutics Inc Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 137. Sage Therapeutics Inc Recent Development
Table 138. SBI Pharmaceuticals Co Ltd Company Details
Table 139. SBI Pharmaceuticals Co Ltd Business Overview
Table 140. SBI Pharmaceuticals Co Ltd Mild Cognitive Impairment Therapeutic Product
Table 141. SBI Pharmaceuticals Co Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 142. SBI Pharmaceuticals Co Ltd Recent Development
Table 143. Suven Life Sciences Ltd Company Details
Table 144. Suven Life Sciences Ltd Business Overview
Table 145. Suven Life Sciences Ltd Mild Cognitive Impairment Therapeutic Product
Table 146. Suven Life Sciences Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 147. Suven Life Sciences Ltd Recent Development
Table 148. Takeda Pharmaceutical Company Ltd Company Details
Table 149. Takeda Pharmaceutical Company Ltd Business Overview
Table 150. Takeda Pharmaceutical Company Ltd Mild Cognitive Impairment Therapeutic Product
Table 151. Takeda Pharmaceutical Company Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 152. Takeda Pharmaceutical Company Ltd Recent Development
Table 153. Therapix Biosciences Ltd Company Details
Table 154. Therapix Biosciences Ltd Business Overview
Table 155. Therapix Biosciences Ltd Mild Cognitive Impairment Therapeutic Product
Table 156. Therapix Biosciences Ltd Revenue in Mild Cognitive Impairment Therapeutic Business (2016-2021) & (US$ Million)
Table 157. Therapix Biosciences Ltd Recent Development
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Mild Cognitive Impairment Therapeutic Market Share by Type: 2020 VS 2027
Figure 2. BAN-2401 Features
Figure 3. Bosutinib Features
Figure 4. Brexanolone Features
Figure 5. CSP-1103 Features
Figure 6. Others Features
Figure 7. Global Mild Cognitive Impairment Therapeutic Market Share by Application: 2020 VS 2027
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Mild Cognitive Impairment Therapeutic Report Years Considered
Figure 12. Global Mild Cognitive Impairment Therapeutic Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Mild Cognitive Impairment Therapeutic Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Mild Cognitive Impairment Therapeutic Market Share by Regions: 2020 VS 2027
Figure 15. Global Mild Cognitive Impairment Therapeutic Market Share by Regions (2022-2027)
Figure 16. Global Mild Cognitive Impairment Therapeutic Market Share by Players in 2020
Figure 17. Global Top Mild Cognitive Impairment Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Mild Cognitive Impairment Therapeutic as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Mild Cognitive Impairment Therapeutic Revenue in 2020
Figure 19. Global Mild Cognitive Impairment Therapeutic Revenue Market Share by Type (2016-2021)
Figure 20. Global Mild Cognitive Impairment Therapeutic Revenue Market Share by Type (2022-2027)
Figure 21. North America Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Mild Cognitive Impairment Therapeutic Market Share by Type (2016-2027)
Figure 23. North America Mild Cognitive Impairment Therapeutic Market Share by Application (2016-2027)
Figure 24. North America Mild Cognitive Impairment Therapeutic Market Share by Country (2016-2027)
Figure 25. United States Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Mild Cognitive Impairment Therapeutic Market Share by Type (2016-2027)
Figure 29. Europe Mild Cognitive Impairment Therapeutic Market Share by Application (2016-2027)
Figure 30. Europe Mild Cognitive Impairment Therapeutic Market Share by Country (2016-2027)
Figure 31. Germany Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Mild Cognitive Impairment Therapeutic Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Mild Cognitive Impairment Therapeutic Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Mild Cognitive Impairment Therapeutic Market Share by Region (2016-2027)
Figure 41. China Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Mild Cognitive Impairment Therapeutic Market Share by Type (2016-2027)
Figure 49. Latin America Mild Cognitive Impairment Therapeutic Market Share by Application (2016-2027)
Figure 50. Latin America Mild Cognitive Impairment Therapeutic Market Share by Country (2016-2027)
Figure 51. Mexico Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Mild Cognitive Impairment Therapeutic Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Mild Cognitive Impairment Therapeutic Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Mild Cognitive Impairment Therapeutic Market Share by Country (2016-2027)
Figure 57. Turkey Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Mild Cognitive Impairment Therapeutic Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. AgeneBio Inc Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 61. Avraham Pharmaceuticals Ltd Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 62. CereSpir Inc Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 63. ConSynance Therapeutics Inc Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 64. Eisai Co Ltd Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 65. Eli Lilly and Company Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 66. Ensol Biosciences Inc Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 67. Genzyme Corp Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 68. IntelGenx Corp Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 69. Krenitsky Pharmaceuticals Inc Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 70. Merck & Co Inc Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 71. Nanotherapeutics Inc Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 72. Neuron Biopharma SA Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 73. Pfizer Inc Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 74. Sage Therapeutics Inc Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 75. SBI Pharmaceuticals Co Ltd Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 76. Suven Life Sciences Ltd Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 77. Takeda Pharmaceutical Company Ltd Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 78. Therapix Biosciences Ltd Revenue Growth Rate in Mild Cognitive Impairment Therapeutic Business (2016-2021)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed


【掲載企業】

AgeneBio Inc、Avraham Pharmaceuticals Ltd、CereSpir Inc、ConSynance Therapeutics Inc、Eisai Co Ltd、Eli Lilly and Company、Ensol Biosciences Inc、Genzyme Corp、IntelGenx Corp、Krenitsky Pharmaceuticals Inc、Merck & Co Inc、Nanotherapeutics Inc、Neuron Biopharma SA、Pfizer Inc、Sage Therapeutics Inc、SBI Pharmaceuticals Co Ltd、Suven Life Sciences Ltd、Takeda Pharmaceutical Company Ltd、Therapix Biosciences Ltd

★調査レポート[世界の軽度認知障害治療市場規模・現状・予測2021-2027] (コード:QY21APR3790)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の軽度認知障害治療市場規模・現状・予測2021-2027]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆